Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes
© 2023 The Authors..
Rationale & Objective: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established.
Study Design: Prospective observational cohort.
Setting & Participants: In the Atherosclerosis Risk in Communities) study, 948 participants were studied.
Exposures: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998.
Outcome: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m2 or dialysis dependence through United States Renal Data System linkage.
Analytical Approach: Logistic regression and C statistics.
Results: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st-5th quintile) to 4%-44%.
Limitations: Biomarkers and creatinine were measured at one time point.
Conclusions: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes.
Plain-Language Summary: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Kidney medicine - 5(2023), 11 vom: 14. Nov., Seite 100719 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Le, Dustin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic kidney disease |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.xkme.2023.100719 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36334232X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36334232X | ||
| 003 | DE-627 | ||
| 005 | 20240326234954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xkme.2023.100719 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM36334232X | ||
| 035 | |a (NLM)37841418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Le, Dustin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma Biomarkers and Incident CKD Among Individuals Without Diabetes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Rationale & Objective: Biomarkers of kidney disease progression have been identified in individuals with diabetes and underlying chronic kidney disease (CKD). Whether or not these markers are associated with the development of CKD in a general population without diabetes or CKD is not well established | ||
| 520 | |a Study Design: Prospective observational cohort | ||
| 520 | |a Setting & Participants: In the Atherosclerosis Risk in Communities) study, 948 participants were studied | ||
| 520 | |a Exposures: The baseline plasma biomarkers of kidney injury molecule-1 (KIM-1), monocyte chemoattractant protein-1 (MCP-1), soluble urokinase plasminogen activator receptor (suPAR), tumor necrosis factor receptor 1 (TNFR-1), tumor necrosis factor receptor 2 (TNFR-2), and human cartilage glycoprotein-39 (YKL-40) measured in 1996-1998 | ||
| 520 | |a Outcome: Incident CKD after 15 years of follow-up defined as ≥40% estimated glomerular filtration rate decline to <60 mL/min/1.73 m2 or dialysis dependence through United States Renal Data System linkage | ||
| 520 | |a Analytical Approach: Logistic regression and C statistics | ||
| 520 | |a Results: There were 523 cases of incident CKD. Compared with a random sample of 425 controls, there were greater odds of incident CKD per 2-fold higher concentration of KIM-1 (OR, 1.49; 95% CI, 1.25-1.78), suPAR (OR, 2.57; 95% CI, 1.74-3.84), TNFR-1 (OR, 2.20; 95% CI, 1.58-3.09), TNFR-2 (OR, 2.03; 95% CI, 1.37-3.04). After adjustment for all biomarkers, KIM-1 (OR, 1.42; 95% CI, 1.19-1.71), and suPAR (OR, 1.86; 95% CI, 1.18-2.92) remained associated with incident CKD. Compared with traditional risk factors, the addition of all 6 biomarkers improved the C statistic from 0.695-0.731 (P < 0.01) and using the observed risk of 12% for incident CKD, the predicted risk gradient changed from 5%-40% (for the 1st-5th quintile) to 4%-44% | ||
| 520 | |a Limitations: Biomarkers and creatinine were measured at one time point | ||
| 520 | |a Conclusions: Higher levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with higher odds of incident CKD among individuals without diabetes | ||
| 520 | |a Plain-Language Summary: For people with diabetes or kidney disease, several biomarkers have been shown to be associated with worsening kidney disease. Whether these biomarkers have prognostic significance in people without diabetes or kidney disease is less studied. Using the Atherosclerosis Risk in Communities study, we followed individuals without diabetes or kidney disease for an average of 15 years after biomarker measurement to see if these biomarkers were associated with the development of kidney disease. We found that elevated levels of KIM-1, suPAR, TNFR-1, and TNFR-2 were associated with the development of kidney disease. These biomarkers may help identify individuals who would benefit from interventions to prevent the development of kidney disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Incident kidney disease | |
| 650 | 4 | |a KIM-1 | |
| 650 | 4 | |a MCP-1 | |
| 650 | 4 | |a TNFR-1 | |
| 650 | 4 | |a TNFR-2 | |
| 650 | 4 | |a YKL-40 | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a plasma biomarkers | |
| 650 | 4 | |a sUPAR | |
| 700 | 1 | |a Chen, Jingsha |e verfasserin |4 aut | |
| 700 | 1 | |a Shlipak, Michael G |e verfasserin |4 aut | |
| 700 | 1 | |a Ix, Joachim H |e verfasserin |4 aut | |
| 700 | 1 | |a Sarnak, Mark J |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Orlando M |e verfasserin |4 aut | |
| 700 | 1 | |a Schelling, Jeffrey R |e verfasserin |4 aut | |
| 700 | 1 | |a Bonventre, Joseph V |e verfasserin |4 aut | |
| 700 | 1 | |a Sabbisetti, Venkata S |e verfasserin |4 aut | |
| 700 | 1 | |a Schrauben, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Coca, Steven G |e verfasserin |4 aut | |
| 700 | 1 | |a Kimmel, Paul L |e verfasserin |4 aut | |
| 700 | 1 | |a Vasan, Ramachandran S |e verfasserin |4 aut | |
| 700 | 1 | |a Grams, Morgan E |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Chirag |e verfasserin |4 aut | |
| 700 | 1 | |a Coresh, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Rebholz, Casey M |e verfasserin |4 aut | |
| 700 | 0 | |a Chronic Kidney Disease Biomarkers Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney medicine |d 2019 |g 5(2023), 11 vom: 14. Nov., Seite 100719 |w (DE-627)NLM303572787 |x 2590-0595 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:11 |g day:14 |g month:11 |g pages:100719 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xkme.2023.100719 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 11 |b 14 |c 11 |h 100719 | ||